Singapore medicines with clinical-trial evidence for a new indication
45 of the 966 medicines with a SgTxGNN report have a TxGNN-predicted new indication graded at evidence level L1 or L2 (11 at L1, 34 at L2), meaning clinical-trial evidence (randomised trials, Phase 2–3 trials or systematic reviews) was found for it.
The medicines come from the registration data of the Health Sciences Authority (HSA), with licence status shown in each drug report; the list reflects the drug reports as last updated on 2026-11-20.
Trial evidence for a predicted indication is not proof of efficacy. Every candidate below still requires clinical validation and regulatory review before any clinical use.
Medicines with trial evidence (L1–L2)
| Drug | Predicted new indication | Evidence level | Registered trials cited (NCT) |
|---|---|---|---|
| Bendamustine | Mantle cell lymphoma | L1 | 10 |
| Busulfan | Myelodysplastic syndrome | L1 | 10 |
| Clofarabine | myeloid leukemia | L1 | 10 |
| Clomipramine | Anxiety disorder | L1 (with caveat) | 8 |
| Doxorubicin | Ewing sarcoma | L1 | 15 |
| Ketamine | Headache disorder | L1 (with caveat) | 8 |
| Nepafenac | Eye disease | L1 | 10 |
| Ofatumumab | Follicular lymphoma | L1 (with caveat) | 12 |
| Peginterferon Alfa-2A | Hepatitis E virus infection | L1 | 10 |
| Polidocanol | Esophageal varices with bleeding | L1 (with caveat) | 0 |
| Tacrolimus | Seborrheic dermatitis | L1 (with caveat) | 2 |
| Acetylcysteine | Thrombotic disease | L2 | 7 |
| Atorvastatin | HIV infectious disease | L2 | 10 |
| Bupropion | attention deficit-hyperactivity disorder | L2 | 6 |
| Clozapine | Manic bipolar affective disorder | L2 | 1 |
| Diazepam | Insomnia (disease) | L2 | 0 |
| Docetaxel | Ewing sarcoma | L2 | 8 |
| Everolimus | Liposarcoma | L2 (with caveat) | 1 |
| Fludarabine | Plasma cell myeloma | L2 | 10 |
| Hydrocortisone | Alopecia areata | L2 | 1 |
| Hydrocortisone Acetate | Alopecia areata | L2 | 1 |
| Ledipasvir | Hepatitis B virus infection | L2 | 5 |
| Lenalidomide | Myeloid leukemia | L2 | 11 |
| Levonorgestrel | Acne (disease) | L2 | 0 |
| Mefenamic Acid | Headache disorder | L2 | 0 |
| Midazolam | Insomnia | L2 | 2 |
| Moclobemide | Agoraphobia | L2 | 0 |
| Montelukast | Bronchitis | L2 (with caveat) | 10 |
| Mycophenolate Mofetil | HIV infectious disease | L2 (with caveat) | 4 |
| Nortriptyline | Attention deficit-hyperactivity disorder | L2 (with caveat) | 0 |
| Oxaliplatin | Malignant pleural mesothelioma | L2 | 3 |
| Pazopanib | Liposarcoma | L2 | 6 |
| Pimecrolimus | Seborrheic dermatitis | L2 | 1 |
| Prednisolone | Alopecia areata | L2 | 0 |
| Prednisone | Alopecia areata | L2 | 0 |
| Propofol | Migraine disorder | L2 | 3 |
| Regorafenib | Liposarcoma | L2 (with caveat) | 1 |
| Risankizumab | Dermatitis | L2 | 2 |
| Ropivacaine | Migraine disorder | L2 (with caveat) | 2 |
| Sofosbuvir | Hepatitis B virus infection | L2 (with caveat) | 11 |
| Sunitinib | Liposarcoma | L2 | 2 |
| Tocilizumab | Ankylosing spondylitis | L2 | 5 |
| Trimebutine | Migraine disorder | L2 (with caveat) | 0 |
| Ustekinumab | Dermatitis | L2 | 6 |
| Vinorelbine | Ewing sarcoma | L2 | 3 |
How to read this list
- Evidence level follows the site's criteria: L1 = Multiple Phase 3 RCTs; L2 = Single RCT or Phase 2. "(with caveat)" means the drug report qualifies the grade; read the note in the report before relying on it.
- Predicted new indication is the main prediction shown in each drug report. Indications and contraindications already recorded in the TxGNN knowledge graph are excluded, but some predictions may still overlap an established use; the report explains this where it applies.
- Registered trials cited counts the ClinicalTrials.gov (NCT) numbers cited in the drug report. Reports cite a selection of the trials found; 0 means the report cites no registered trial, and its literature evidence section shows the basis for the grade.
- For all levels and the full method, see High Evidence (L1-L2), Drug List and the methodology.
Disclaimer
This report is for academic research purposes only and does not constitute medical advice. Please follow physician instructions for medication use. Any drug repurposing decisions require complete clinical validation and regulatory approval.
Reviewer: 藥提醒科技有限公司 (yao.care)
This report is for academic research purposes only and does not constitute medical advice. Please follow physician instructions for medication use. Any drug repurposing decisions require complete clinical validation and regulatory approval.
Reviewer: 藥提醒科技有限公司 (yao.care)